Your institution may have access to this item. Find your institution then sign in to continue.
Title
Focus on sepsis.
Abstract
The article focuses on the development of drugs for sepsis, a blood disorder. Eli Lilly & Co. withdrew the only approved drug for sepsis that was named as Xigris, a recombinant from of activated protein C from global markets due to failure in trial practice on several people. The physicians are discovering new drugs for the disease. It is focused that the mortality rates from sepsis are dropping day by day due to the improvements in hospital care and awareness of this deadly disease.